BCAX 8-K: SEC filing

Filed with the SEC on Nov 9, 2026 · accession 0001628280-26-071886

BCAX filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Bicara Therapeutics furnished a press release announcing its financial results for the quarter ended September 30, 2026, along with other business updates.

For details, click here →How to read a 8-K →

Key details

RegistrantBicara Therapeutics Inc.

President, interim chief executive officer and chief operating officerRyan Cohlhepp, Pharm.D

✦ Ask GOAX AI about this filing — what it means for BCAX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BCAX?

Click here

Frequently asked questions

What did BCAX file with the SEC on Nov 9, 2026?

BCAX filed a 8-K (SEC filing). Bicara Therapeutics furnished a press release announcing its financial results for the quarter ended September 30, 2026, along with other business updates.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other BCAX SEC filings

Get alerts when BCAX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

BCAX overview BCAX analysis BCAX news Latest SEC filings